SynAct Pharma to Present at Redeye Autoimmune and Inflammatory Diseases Event

SynAct Pharma AB ( (SE:SYNACT) ) just unveiled an update.

SynAct Pharma AB announced its participation in the Redeye Autoimmune and Inflammatory Diseases event in Stockholm, where the company’s Chief Business Officer, Mads Bjerregaard, will present updates on their lead compound, resomelagon. This potential first-in-class, non-suppressive immune system modulator is being developed for treating rheumatoid arthritis and acute inflammation due to viral infections, highlighting SynAct’s innovative approach in the field of immunology.

More about SynAct Pharma AB

SynAct Pharma AB is a clinical-stage biotechnology company listed on Nasdaq Stockholm, focusing on resolving inflammation through the selective activation of the melanocortin system. The company offers a broad portfolio of oral and injectable selective melanocortin agonists designed to induce anti-inflammatory and inflammation resolution activities, aiding patients in achieving immune balance.

Average Trading Volume: 180,181

Technical Sentiment Signal: Buy

Current Market Cap: SEK1.13B

See more data about SYNACT stock on TipRanks’ Stock Analysis page.